<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20050630//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Bioinformation</journal-id><journal-id journal-id-type="iso-abbrev">Bioinformation</journal-id><journal-id journal-id-type="publisher-id">Bioinformation</journal-id><journal-title-group><journal-title>Bioinformation</journal-title></journal-title-group><issn pub-type="epub">0973-2063</issn><publisher><publisher-name>Biomedical Informatics</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6900319</article-id><article-id pub-id-type="publisher-id">97320630015760</article-id><article-id pub-id-type="doi">10.6026/97320630015760</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>From EST to structure models for functional inference of APP, BACE1, PSEN1, PSEN2 genes</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Aathi</surname><given-names>Muthusankar</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="COR1">*</xref></contrib><contrib contrib-type="author"><name><surname>Piramanayagam</surname><given-names>Shanmughavel</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><aff id="A1"><label>1</label>Computational Biology Lab, Department of Bioinformatics, Bharathiar University, Coimbatore-641046, Tamil Nadu, India</aff></contrib-group><author-notes><corresp id="COR1"><label>*</label>Muthusankar Aathi <email>muthubioinf@gmail.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>31</day><month>10</month><year>2019</year></pub-date><volume>15</volume><issue>10</issue><fpage>760</fpage><lpage>771</lpage><history><date date-type="received"><day>22</day><month>9</month><year>2019</year></date><date date-type="rev-recd"><day>28</day><month>10</month><year>2019</year></date><date date-type="accepted"><day>29</day><month>10</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 Biomedical Informatics</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.</license-p></license></permissions><abstract><p>Successive oxidative stress and biochemical changes results in neuronal death and neuritic plaques growth in Alzheimer's disease (AD).
Therefore, it is interest to analyze amyloid-&#x003b2;eta precursor protein (APP), beta-secretase 1 (BACE1), presenilin (PSEN1 and PSEN2) genes
from brain tissues to gain insights. Development of potential inhibitors for these targets is of significance. EST sequences of 2898 (APP),
539 (BACE1), 786 (PSEN1) and 314 (PSEN2) genes were analyzed in this study. A contig sequences with APP (contigs 1-4), BACE1 (contigs 5-7),
PSEN1 (contigs 8, 9, 10, 11), PSEN2 (contigs 13, 14) except PSEN1 (contigs 10) and PSEN2 (contigs 13) genes were identified. APP (contig 3
without translational error) was further analyzed using molecular modeling and docking to show its binding with curcumin (principal curcuminoid of turmeric)
having -7.3 kcal/mol interaction energy for further consideration as a potential inhibitor. </p></abstract><kwd-group><kwd>Alzheimer's disease</kwd><kwd>Curcumin</kwd><kwd>Hypothetical protein</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>Background</title><p>Alzheimer's disease (AD) is caused due to the structural and functional loss of neurons which shows symptoms like cognitive and memory deterioration, progressive destruction of 
intellectual activities in day to life and behavioral abnormalities [<xref rid="R01" ref-type="bibr">1</xref>]. About 36 million people were found to be affected by AD worldwide in 2010 and it was anticipated to rise 
66 million by 2030 and 115 million by 2050 [<xref rid="R02" ref-type="bibr">2</xref>]. In India, 3.7 million people were affected by AD [<xref rid="R03" ref-type="bibr">3</xref>] and the number of people having AD. Prevalence increases exponentially with 
age, affecting a little more than 1% in the population aged 65-69 years up to as much as 30-40% in the oldest old [<xref rid="R04" ref-type="bibr">4</xref>]. Alzheimer's disease is mainly caused due to the accumulation 
of &#x003b2;-amyloid peptides [<xref rid="R05" ref-type="bibr">5</xref>], which are formed by the action of sequential cleaving of the APP gene which plays an important role in the central nervous system. Proteolytic cleavage 
of APP by &#x003b2;- and &#x003b3;-secretase enzymes resulting in the release of neurotoxic A&#x003b2; peptides which can aggregate into oligomer is known. A mutation in the APP gene is likely to inhibit 
&#x003b1;-secretase cleavage which further enables preferential cleavage by &#x003b2;-secretase. Mutations in the PSEN1 and PSEN2 genes (which are components of the &#x003b3;-secretase complex) results in 
increased cleavage by &#x003b3;-secretase at this site. Both these conditions result in the excess production of A&#x003b2; peptide. Eventually, subsequent oxidative stress and biochemical changes 
result in the neuronal death and development of neuritic plaques in AD [<xref rid="R06" ref-type="bibr">6</xref>].</p><p>Expressed sequence tags are sequenced regions of complementary deoxyribonucleic acid (cDNA) imitates of messenger ribonucleic acid (mRNA) that are expressed in different states 
and represents element of the transcribed portion of the genome. The EST sequence information plays a vital role in human biology and disease, such as neurological disorders [<xref rid="R07" ref-type="bibr">7</xref>]. 
This helps to identify the functional genes expressed in diseased condition. Mutations in the alzheimer's susceptibility genes APP, BACE1, PSEN1 and PSEN2 greatly increase the risk 
of AD. The approved drugs for AD namely, tacrine, donepezil, rivastigmine and galantamine failed due to severe side effects and were abandoned. This work will helpto identify the 
functional annotation of APP, BACE1, PSEN1, PSEN2 genes and new discovery for the development of novel therapeutic approaches for the treatment of AD.</p></sec><sec id="s2"><title>Methodology</title><sec id="s2a"><title>Retrieval of ESTs sequence and assembly:</title><p>In silico analysis of AD human genes APP, BACE1, PSEN1 and PSEN2 taken from UniGene database and those genes originating from brain tissues were taken. 
The 5' ESTs were considered, as the ESTs generated from the 3' end are most error prone as of the low base-call quality at the start of sequence reads. 
The 5' EST sequences were extracted using contig assembly program by CAP3 server [<xref rid="R08" ref-type="bibr">8</xref>]. The default parameters were used and each gene sequences were submitted 
to DNA sequence assembly program (CAP3) server in FASTA formatted text file and result was displayed in different output files e.g. contigs, single sequences, 
Assembly details and sequence file. We have selected contig sequence data set as it is useful functionality ascertained.</p></sec><sec id="s2b"><title>Conceptual translation of ESTs and functional annotation:</title><p>ESTScan is a program that can identify the coding regions in DNA sequences and this was translated into amino acid sequences at either N- or C-terminus. 
Each contig sequence was generated by ESTScan2 tool [<xref rid="R10" ref-type="bibr">10</xref>]. Finally, the amino acid sequences were selected using multiple sequence alignment by CLC Genomics 
Workbench and further functional annotations were carried out. Our translated protein sequences for each sequence were generated by InterProScan 5.0 [<xref rid="R11" ref-type="bibr">11</xref>].</p></sec><sec id="s2c"><title>Molecular modelling of hypothetical protein:</title><p>Structural annotation of APP hypothetical amino acid sequence was used for build a 3D structure by Modeller v9.13 software [<xref rid="R12" ref-type="bibr">12</xref>]. The hypothetical protein sequence was 
aligned in BLASTP against the Protein Data Bank (PDB) database to select their appropriate templates. The template was selected for hypothetical protein query sequence 
aligning 18-199 amino acid residues, showing 97% sequence identity with 3KTM [<xref rid="R13" ref-type="bibr">13</xref>]; aligning 342-551 amino acid residues shows 99% sequence identity with 3NYL [<xref rid="R14" ref-type="bibr">14</xref>] and 
aligning 652-751 amino acid residues shows 100% sequence identify with 2LP1 [<xref rid="R15" ref-type="bibr">15</xref>]. </p><p>These templates were used to build a 3D structure for homology modelling. Modelled structure was energy minimized using Swiss-PDB viewer program (Gromos96 force field). 
Theoretically predicted structure was visualized using PyMol visualization software. The amino acid constraint validation of the modeled APP protein was done by PROCHECK program 
(www.ebi.ac.uk/ thornton-srv/software/PROCHECK/) [<xref rid="R16" ref-type="bibr">16</xref>]. Further, 3D profile of the modelled protein was computed by Verify3D program.</p></sec><sec id="s2d"><title>Selection of ligands:</title><p>The 2D structure of synthetic compounds tacrine, donepezil, rivastigmine, galantamine and natural remedy like compounds from plants such as Rosmarinus officinalis 
(&#x003b1;-Pinene, Camphene, &#x003b2;-Pinene, 1,8-Cineole, &#x003b1;-Thujone, &#x003b2;-Thujone, Chrysanthenone, Camphor, (+)-Borneol, Bornyl acetate, &#x003b1;-Copaene, Trans-Caryophyllene, &#x003b1;-Humulene, 
Germacrene-D and (+) -&#x003b4;-Cadinene); Ginkgo biloba (Quercetin, Kaempferol, Isorhamnetin, Ginkgolide A, B, C, J, M); Panax ginseng (Ginsenoside Rb1 and Rg1); Curcuma Longa 
(Curcumin, Demethoxycurcumin and Bisdemethoxycurcumin); Salvia officinalis (Borneol, Caryophyllene, Linalool); Huperzia serrata (Huperzine A, B and Lycopodine) ; Melissa 
officinalis (1-Octen-3-ol, 6-Methyl-5-hepten-2-one, Myrcene, (Z)-&#x003b2;-Ocimene, (E)-&#x003b2;-Ocimene, n-Nonanal, Cis-Rose oxide, (+)-Trans-Rose oxide, (+)-Trans-Limonene oxide, Citronellal, 
Menthol, Isomenthol, Nerol, Neral, Piperitone, Geraniol, Geranial, &#x003b1;-Cubebene, Geranyl acetate, &#x003b2;-Cubebene, &#x003b2;-Caryophyllene, Valencene, Caryophyllene oxide, 1-Hexadecene, n-Eicosane,
n-Heneicosane); Withania somnifera (Propane,1,1-diethoxy-2-methyl-, 2-Nonanone, PhenylethylAlcohol, Amyl nitrite, Dodecanoic acid, 3-ter-Butyl-4-hydroxyanisole, Tetradecanoic acid, 
n-Hexadecanoic acid, 9-Octadecenal, 1-tridecyne, Oleic acid); Baccopa monnieri (2-octanol, Dimethoxane, 2-Methyl-1-Phenyl-1-butanol, Phytol, Phytol acetate, Octadecanamide); 
Centella asiatica (Thujopsene, &#x003b1;-Thujene, Eucalyptol, 3-Nonen-2-one, &#x003b2;-Linalool, L-Camphor, trans-Borneol, &#x003b1;&#x02013;Terpeneol, Cis-Geraniol, Isobornyl acetate, 7-Tetradecene, &#x003b2;-Elemene, 
&#x003b2;-Gurjunene, &#x003b3;-Elemene, Isocaryophyllene, Aromadendrene, &#x003b2;-Farnesene, &#x003b2;-Acoradiene, &#x003b2;-Selinene, &#x003b1;-Selinene, &#x003b1;-Chamigrene, &#x003b1;-Panasinsen, -(-)Spathulenol, Viridiflorol, Valeranone, 
Isoaromadendrene epoxide, Aristolene epoxide, 1-Naphthalenol); Celastrus paniculatus (Palmitic acid, Erucic acid, &#x003b3;-Muurolene, Cubenol) were downloaded from PubChem databases as .
sdf format. Further, the .sdf format converted into .pdb format using Openbabel 2.3.2.</p></sec><sec id="s2e"><title>Molecular docking:</title><p>Docking studies was carried out using Glide module from Schrodinger suite [<xref rid="R17" ref-type="bibr">17</xref>] to find the interaction between modeled APP protein with natural and synthetic compounds. 
All the compounds were prepared by LigPrep Module. The protein grids were prepared with the mutated residues and the size of the bounding box was set to 30&#x000c5;. Modelled APP protein 
coordinates file of enclosing box was set as x=3.9023&#x000c5;; y=32.884&#x000c5;; z=30&#x000c5; respectively. All the prepared inhibitory compounds were docked against the grid generated APP modelled 
protein. The inhibitory compounds used for docking was screened using Virtual screening. Glide score was selected as the scoring function to rank the poses of each inhibitory 
compound. Validation of the docking is useful technique to identify best docked complex among number of docked complex.</p></sec></sec><sec id="s3"><title>Results and Discussion:</title><sec id="s3a"><title>Retrieval of ESTs sequence:</title><p>The EST sequences for human AD genes APP, BACE1, PSEN1 and PSEN2 were searched from UniGene database. The gene entries with their mRNA and ESTs information are listed in <xref rid="T1" ref-type="table">Table 1</xref> 
ESTs of four gene entries originating from brain tissue were used for further analysis.</p></sec><sec id="s3b"><title>EST clustering and assembly:</title><p>Each gene sequence of ESTs from brain tissue was retrieved. The 5' ESTs were analyzed, as the ESTs created from the 3' end are most error prone because of the low base-call 
quality at the start of sequence reads. The subjected ESTs along with their resulting contigs found a total of 988 ESTs from four reported gene entries as listed in Table 5 
(Supplementary Material Available in the PDF version). The tissue-based ESTs from four reported genes were subjected to cluster analysis by CAP3 Server. 14 contigs of four genes 
were found and further analysis was under taken.</p></sec><sec id="s3c"><title>Database similarity searches:</title><p>The database similarity search by querying these contigs in BLAT against human genome revealed that alzheimer's contig of APP shows good matches with chromosomes 21. The BACE1, 
PSEN1 and PSEN2 contigs were showing good matches with chromosomes 11, 14 and 1 respectively and are shown in <xref rid="T2" ref-type="table">Table 2</xref>. The conceptual translation of 14 contigs sequences in ESTScan2 
provides 12 protein sequences from APP, BACE1, PSEN1 and PSEN2, as presented in this analysis and protein sequences were not available for the rest of two contig nucleotide sequences 
contig 10 and contig 13. Multiple sequence alignment was done for these 12 protein sequences obtained by ESTScan2 tool. The entire alignment shows contig 3 sequence of APP protein 
alone with no error at translate level and rest of the 11 protein sequences were left due to some erroneous readings (X, which does not code for somewhat amino acids or refers to a 
stop codon) in their sequence as shown in <xref ref-type="fig" rid="F1">Figure 1</xref>, obtained by CLC Genomics Workbench 7.6. The APP protein sequence of contig 3 is 751 amino acids with a molecular weight of 
84818.77 Daltons and this sequence was named as hypothetical protein for further annotation.</p></sec><sec id="s3d"><title>Conceptual translation of ESTs</title><p>The APP protein sequence was reported from 5' ESTs of brain tissues and it belongs to the APP amyloid and beta-APP families of proteins with a distinct N-terminal and C-terminal. 
The major part of the amyloid plaques found in the brains of AD and peptide regions of 36-43 amino acids are fatefully involved in amyloid precursor protein. A&#x003b2; molecules can 
aggregate to form oligomers and the resulting amyloid plaques are toxic to nerve cells [<xref rid="R18" ref-type="bibr">18</xref>]. N-terminal region of the APP is a member of the heparin-binding class of GFLDs 
(Growth Factor-Like Domain) and may itself have growth factor function, neuronal development. It contains four structurally similar domains represented by PFAM families PF12925 
[<xref rid="R14" ref-type="bibr">14</xref>],PF02177 [<xref rid="R19" ref-type="bibr">19</xref>], PF12924 [<xref rid="R20" ref-type="bibr">20</xref>] and PF00014 [<xref rid="R21" ref-type="bibr">21</xref>] as shown in <xref rid="T3" ref-type="table">Table 3</xref>. In structural classification by CATH, the classification lineage of hierarchy 3.90.570.10, 3.30.1490.140, 
4.10.230.10 is amyloid beta A4 protein; 1.10.287.510 is amyloid protein and 4.10.410.10 is protease inhibitor IX.</p></sec><sec id="s3e"><title>Molecular modelling of hypothetical protein:</title><p>The 3D structure of hypothetical protein of human APP was predicted using MODELLER v9.13. This program was generated ten different 3D modeled structures and validating these 
structures was considered based on the scoring percentage of the favored regions. Finally, we selected the best modeled structure for hypothetical protein (model 3) as depicted 
in <xref ref-type="fig" rid="F2">Figure 2A</xref>. Validation of Ramachandran plot showed &#x0003e;96% of the residues in most favored and additional allowed regions and the structure of our modeled protein was found to be 
stable. Verify3D methods evaluate protein structure using 3D profiles and this program analyzed the compatibility of an atomic model (3D) with their possess amino acid sequence 
(1D). Each residue is allocated a structural class based on the scores ranges from -1 to +1. In our results verify3D score value of modeled APP protein is -1.0 to 0.7 (<xref ref-type="fig" rid="F2">Figure 2B</xref>). 
Validation results showed stero chemical properties and geometrical arrangements of the atoms of the protein was stable. The root-mean-square deviation value of modeled APP protein 
3D structure was higher (0.439&#x000c5;) than the existing crystal structure PDB IDs: 3KTM (2.70&#x000c5;) and 3NYL (2.80&#x000c5;) with an energy value of -30227.773KJ/mol.</p></sec><sec id="s3f"><title>Molecular docking:</title><p>Molecular docking studies were performed for modeled complete sequences of APP protein with current drugs and medicinal compounds. Various synthetic drugs are available against 
AD such as tacrine, donepezil, rivastigmine and galantamine, but causing side effects like diarrhea, nausea, vomiting etc [<xref rid="R22" ref-type="bibr">22</xref>]. Hence, a new drug development is important to cure AD 
without these side effects. In our study, we have selected 11 medicinal plants such as R. officinalis (&#x003b1;-Pinene, Camphene, &#x003b2;-Pinene, 1,8-Cineole, &#x003b1;-Thujone, &#x003b2;-Thujone, Chrysanthenone, 
Camphor, (+)-Borneol, Bornyl acetate, &#x003b1;-Copaene, Trans-Caryophyllene, &#x003b1;-Humulene, Germacrene-D and (+)-&#x003b4;-Cadinene) plant essential oils have a potent effect in patients with symptoms 
of AD [<xref rid="R23" ref-type="bibr">23</xref>] and mentioned 15 natural compounds were identified in this plant using GC-MS analysis. G.biloba extract from leaves has been found to improve the symptoms of AD [<xref rid="R24" ref-type="bibr">24</xref>] and this 
plant compounds like Quercetin, Kaempferol, Isorhamnetin, Ginkgolide A, B, C, J, M. P.ginseng plant extract from root has a potential role in the treatment AD29 and compounds like Ginsenoside 
Rb1 and Rg1. C.Longa Linn plant extract from root have been used to treat of AD and compounds like Curcumin, Demethoxycurcumin and Bisdemethoxycurcumin [<xref rid="R25" ref-type="bibr">25</xref>]. S.officinalis extract from leaf 
has been found a significant benefit in cognition to the patients with mild to moderate AD and compounds like Borneol, Caryophyllene, Linalool. H. serrata has been studied extensively for it 
is role in treating AD and this plant leaves had been extracted to identify compounds like Huperzine A, B and Lycopodine. The essential oil is obtained from leaves of M.officinalis compounds 1-Octen-3-ol, 
6-Methyl-5-hepten-2-one, Myrcene, (Z)-&#x003b2;-Ocimene, (E)-&#x003b2;-Ocimene, n-Nonanal, Cis-Rose oxide, (+)-Trans-Rose oxide, (+)-Trans-Limonene oxide, Citronellal, Menthol, Isomenthol, Nerol, Neral, Piperitone, Geraniol, 
Geranial, &#x003b1;-Cubebene, Geranyl acetate, &#x003b2;-Cubebene, &#x003b2;-Caryophyllene, Valencene, Caryophyllene oxide, 1-Hexadecene, n-Eicosane, n-Heneicosane [<xref rid="R26" ref-type="bibr">26</xref>] and this plant has been modulate mood and cognitive performance in AD. 
Compounds like Propane,1,1-diethoxy-2-methyl-, 2-Nonanone, PhenylethylAlcohol, Amyl nitrite, Dodecanoic acid, 3-ter-Butyl-4-hydroxyanisole, Tetradecanoic acid, n-Hexadecanoic acid, 9-Octadecenal, 1-tridecyne, 
Oleic acid extracted from W.somnifera root [<xref rid="R27" ref-type="bibr">27</xref>] are mainly used to treat AD. B.monnieri leaf extract has been used to promote memory increasing activity and treat psycho neurological disorders. GC-MS analysis of 
this plant identified compounds such as 2-octanol, Dimethoxane, 2-Methyl-1-Phenyl-1-butanol, Phytol, Phytol acetate, Octadecanamide [<xref rid="R28" ref-type="bibr">28</xref>]. C.asiatica plant essential oil extract from leaves and GC-MS analysis compounds 
like Thujopsene, &#x003b1;-Thujene, Eucalyptol, 3-Nonen-2-one, &#x003b2;-Linalool, L-Camphor, trans-Borneol, &#x003b1;&#x02013;Terpeneol, Cis-Geraniol, Isobornyl acetate, 7-Tetradecene, &#x003b2;-Elemene, &#x003b2;-Gurjunene, &#x003b3;-Elemene, Isocaryophyllene, Aromadendrene, 
&#x003b2;-Farnesene, &#x003b2;-Acoradiene, &#x003b2;-Selinene, &#x003b1;-Selinene, &#x003b1;-Chamigrene, &#x003b1;-Panasinsen, -(-)Spathulenol, Viridiflorol, Valeranone, Isoaromadendrene epoxide, Aristolene epoxide, 1-Naphthalenol. This plant has ability to prevent 
cognitive deficits treatment for AD. C.paniculatus plant contains essential oil extract from seeds and GC-MS analysis compounds like Palmitic acid, Erucic acid, &#x003b3;-Muurolene, Cubenol. The seed oil is studied as best nervine 
tonic and used in treatment of various neurological disorders [<xref rid="R29" ref-type="bibr">29</xref>]. We validated the efficacy of synthetic and medicinal plants based compounds with modeled APP protein using molecular docking approach to identify the best inhibitor for AD.</p><p>APP is a transmembrane protein without known function that is constitutively cleaved into peptides during cell metabolism. The amyloidogenic 40 or 42 amino acid A&#x003b2; peptide is 
released after cleavage by &#x003b2;-secretase and &#x003b3;-secretase. Familial alzheimer's disease (FAD) mutations have been identified in APP, PSEN1 and PSEN2 genes, which are essential for the 
generation of A &#x003b2; peptides [<xref rid="R30" ref-type="bibr">30</xref>]. Reported APP mutation sequences include A673V [<xref rid="R31" ref-type="bibr">31</xref>], V717I [<xref rid="R32" ref-type="bibr">32</xref>]. <xref ref-type="fig" rid="F3">Figure 3</xref> shows the interaction of modeled APP protein with curcumin having least glide 
score value of -7.3Kcal/mol and more number of hydrogen bonds (ARG566, VAL673) were formed than other compounds. From the results of docking study, out of 11 medicinal plant compounds only 
six medicinal plants such as P. ginseng (Ginsenoside Rb1), C. longa Linn (Curcumin), C. asiatica (Aristolene epoxide, Valeranone), B. monnieri (Phytol acetate), B. monnieri (Dimethoxane), C. 
paniculatus (Erucic acid) and synthetic (Rivastigmine, Tacrine, Galantamine) compounds showed proper interaction but mutated residues docked with ginsenoside rb1 and curcumin compounds (<xref rid="T4" ref-type="table">Table 4</xref>). 
Tang and Taghibiglou 2017 [<xref rid="R33" ref-type="bibr">33</xref>] has reported curcumin compound to be more effective than current treatment of AD. Alcigir et al. [<xref rid="R34" ref-type="bibr">34</xref>] found that positive results in new-born rodent pups, curcumin 
compound as a natural therapy for permanent treatment based on neuronal impairment. Abdolahi et al. [<xref rid="R35" ref-type="bibr">35</xref>] has considered curcumin compound as a novel promising therapy in migraine prevention. From the 
molecular interaction study, we conclude that, natural compound curcumin shows better interaction than synthetic, other natural screened compounds and AD approved drugs. Hence we suggested as an alternative 
lead compound of curcumin in alzheimer's disease research.</p></sec></sec><sec id="s4"><title>Conclusion</title><p>EST analysis of the four genes associated with AD produced 14 contig sequences. APP contig 3, the only contig with no error of translation was annotated using functional 
and structural data. APP was further analyzed using molecular modeling and docking with natural compound of curcumin, it shows the best glide score of -7.3kcal/mol into mutated 
residues unlike the synthetic and other natural compounds. Hence to avoid the side effects of synthetic drugs and natural compound, curcumin is suggested for the treatment of AD.</p></sec></body><back><ack><p>We would like to thank University Grant Commission (UGC-MRP) for funding this research by providing Project Fellow to Muthusankar Aathi and DBT-BIF facility for providing 
the software facility.</p></ack><fn-group><fn fn-type="COI-statement"><p>The authors confirm that this article content has no conflict of interest.</p></fn></fn-group><fn-group><fn id="FN" fn-type="other"><p><bold>Edited by P Kangueane</bold></p></fn></fn-group><fn-group><fn id="FN1" fn-type="other"><p><bold>Citation: </bold>Aathi and Piramanayagam Bioinformation 15(10):760-771 (2019)</p></fn></fn-group><ref-list><title>References</title><ref id="R01"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>JL</given-names></name><etal/></person-group><source>New England Journal of Medicine </source><year>2004</year><volume>351</volume><fpage>56</fpage><?supplied-pmid 15229308?><pub-id pub-id-type="pmid">15229308</pub-id></element-citation></ref><ref id="R02"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>A</given-names></name><etal/></person-group><source>CNS Neurol Disord Drug Targets </source><year>2018</year><volume>17</volume><fpage>571</fpage><?supplied-pmid 29952273?><pub-id pub-id-type="pmid">29952273</pub-id></element-citation></ref><ref id="R03"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peter</surname><given-names>KP</given-names></name><name><surname>Emily</surname><given-names>RA</given-names></name></person-group><source>Neuroscience and Medicine </source><year>2011</year><volume>2</volume><fpage>120</fpage></element-citation></ref><ref id="R04"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gatz</surname><given-names>M</given-names></name><etal/></person-group><source>Neurobiology of aging </source><year>2005</year><volume>26</volume><fpage>439</fpage><?supplied-pmid 15653172?><pub-id pub-id-type="pmid">15653172</pub-id></element-citation></ref><ref id="R05"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tharp</surname><given-names>WG</given-names></name><name><surname>Sarkar</surname><given-names>IN</given-names></name></person-group><source>BMC genomics </source><year>2013</year><volume>14</volume><fpage>1</fpage><?supplied-pmid 23627794?><pub-id pub-id-type="pmid">23323973</pub-id></element-citation></ref><ref id="R06"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patterson</surname><given-names>C</given-names></name><etal/></person-group><source>Canadian Medical Association Journal </source><year>2008</year><volume>178</volume><fpage>548</fpage><?supplied-pmid 18299540?><pub-id pub-id-type="pmid">18299540</pub-id></element-citation></ref><ref id="R07"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemere</surname><given-names>CA</given-names></name><etal/></person-group><source>The American journal of pathology </source><year>2004</year><volume>165</volume><fpage>283</fpage><?supplied-pmid 15215183?><pub-id pub-id-type="pmid">15215183</pub-id></element-citation></ref><ref id="R08"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Madan</surname><given-names>A</given-names></name></person-group><source>Genome research </source><year>1999</year><volume>9</volume><fpage>868</fpage><?supplied-pmid 10508846?><pub-id pub-id-type="pmid">10508846</pub-id></element-citation></ref><ref id="R09"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kent</surname><given-names>WJ</given-names></name></person-group><source>Genome research </source><year>2002</year><volume>12</volume><fpage>656</fpage><?supplied-pmid 11932250?><pub-id pub-id-type="pmid">11932250</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iseli</surname><given-names>C</given-names></name><etal/></person-group><source>In ISMB </source><year>1999</year><volume>99</volume><fpage>138</fpage><?supplied-pmid 10786296?><pub-id pub-id-type="pmid">10786296</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quevillon</surname><given-names>E</given-names></name><etal/></person-group><source>Nucleic acids research </source><year>2005</year><volume>33</volume><fpage>116</fpage><?supplied-pmid 15980438?><pub-id pub-id-type="pmid">15980438</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x00160;ali</surname><given-names>A</given-names></name><name><surname>Blundell</surname><given-names>TL</given-names></name></person-group><source>Journal of molecular biology </source><year>1993</year><volume>234</volume><fpage>779</fpage><?supplied-pmid 8254673?><pub-id pub-id-type="pmid">8254673</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahms</surname><given-names>SO</given-names></name><etal/></person-group><source>Proceedings of the National Academy of Sciences </source><year>2010</year><volume>107</volume><fpage>5381</fpage><?supplied-pmid 20212142?><pub-id pub-id-type="pmid">20212142</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Ha</surname><given-names>Y</given-names></name></person-group><source>Molecular cell </source><year>2004</year><volume>15</volume><fpage>343</fpage><?supplied-pmid 15304215?><pub-id pub-id-type="pmid">15304215</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>PJ</given-names></name><etal/></person-group><source>Science </source><year>2012</year><volume>336</volume><fpage>1168</fpage><?supplied-pmid 22654059?><pub-id pub-id-type="pmid">22654059</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laskowski</surname><given-names>RA</given-names></name><etal/></person-group><source>Journal of applied crystallography </source><year>1993</year><volume>26</volume><fpage>283</fpage></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="other"><collab>Schrodinger, LLC, New York, USA</collab><source>GLIDE, Version 5.8</source><year>2012</year></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pulawski</surname><given-names>W</given-names></name><etal/></person-group><source>Applied biochemistry and biotechnology </source><year>2012</year><volume>166</volume><fpage>1626</fpage><?supplied-pmid 22350870?><pub-id pub-id-type="pmid">22350870</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossjohn</surname><given-names>J</given-names></name><etal/></person-group><source>Nature Structural and Molecular Biology </source><year>1999</year><volume>6</volume><fpage>327</fpage><?supplied-pmid 10201399?><pub-id pub-id-type="pmid">10201399</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>GKW</given-names></name><etal/></person-group><source>Journal of molecular biology </source><year>2007</year><volume>367</volume><fpage>148</fpage><?supplied-pmid 17239395?><pub-id pub-id-type="pmid">17239395</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnoux</surname><given-names>B</given-names></name><etal/></person-group><source>Acta Crystallographica Section D: Biological Crystallography </source><year>2002</year><volume>58</volume><fpage>1252</fpage><?supplied-pmid 12077460?><pub-id pub-id-type="pmid">12077460</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hake</surname><given-names>AM</given-names></name></person-group><source>Cleveland Clinic journal of medicine </source><year>2001</year><volume>68</volume><fpage>608</fpage><?supplied-pmid 11453078?><pub-id pub-id-type="pmid">11453078</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozarowski</surname><given-names>M</given-names></name><etal/></person-group><source>Herba Polonica </source><year>2009</year><volume>55</volume><fpage>148</fpage></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><source>Nutrients </source><year>2018</year><volume>10</volume><fpage>589</fpage><?supplied-pmid 29747475?><pub-id pub-id-type="pmid">29747475</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iriti</surname><given-names>M</given-names></name><etal/></person-group><source>Molecules </source><year>2010</year><volume>15</volume><fpage>3517</fpage><?supplied-pmid 20657497?><pub-id pub-id-type="pmid">20657497</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdellatif</surname><given-names>F</given-names></name><etal/></person-group><source>EXCLI Journal </source><year>2014</year><volume>13</volume><fpage>772</fpage><?supplied-pmid 26417300?><pub-id pub-id-type="pmid">26417300</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S</given-names></name><etal/></person-group><source>Int. J. Pharm. Phytochem. Res </source><year>2011</year><volume>3</volume><fpage>31</fpage></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subashri</surname><given-names>B</given-names></name><name><surname>Pillai</surname><given-names>YJ</given-names></name></person-group><source>Int J Pharm Pharm Sci </source><year>2014</year><volume>6</volume><fpage>494</fpage></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arora</surname><given-names>N</given-names></name><name><surname>Pandey-Rai</surname><given-names>S</given-names></name></person-group><source>Industrial Crops and Products </source><year>2014</year><volume>61</volume><fpage>345</fpage></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Strooper</surname><given-names>B</given-names></name><etal/></person-group><source>Nature Reviews Neurology </source><year>2010</year><volume>6</volume><fpage>99</fpage><?supplied-pmid 20139999?><pub-id pub-id-type="pmid">20139999</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Fede</surname><given-names>G</given-names></name><etal/></person-group><source>Science </source><year>2009</year><volume>323</volume><fpage>1473</fpage><?supplied-pmid 19286555?><pub-id pub-id-type="pmid">19286555</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goate</surname><given-names>A</given-names></name><etal/></person-group><source>Nature </source><year>1991</year><volume>349</volume><fpage>704</fpage><?supplied-pmid 1671712?><pub-id pub-id-type="pmid">1671712</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>M</given-names></name><name><surname>Changiz</surname><given-names>T</given-names></name></person-group><source>Journal of Alzheimer's Disease </source><year>2017</year><volume>58</volume><fpage>1003</fpage><?supplied-pmid 28527218?><pub-id pub-id-type="pmid">28527218</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alcigir</surname><given-names>ME</given-names></name><etal/></person-group><source>CNS Neurol Disord Drug Targets </source><year>2018</year><volume>17</volume><fpage>132</fpage><?supplied-pmid 29546838?><pub-id pub-id-type="pmid">29546838</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdolahi</surname><given-names>M</given-names></name><etal/></person-group><source>CNS Neurol Disord Drug Targets </source><year>2018</year><volume>17</volume><fpage>430</fpage><?supplied-pmid 29938621?><pub-id pub-id-type="pmid">29938621</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="T1" position="float"><label>Table 1</label><caption><title>UniGene information on human Alzheimer's disease</title></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1">S.No</td><td rowspan="1" colspan="1">Name of the Genes</td><td rowspan="1" colspan="1">Source</td><td rowspan="1" colspan="1">mRNA</td><td rowspan="1" colspan="1">ESTs</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">1.</td><td rowspan="1" colspan="1">APP</td><td rowspan="1" colspan="1">Homo sapiens</td><td rowspan="1" colspan="1">38</td><td rowspan="1" colspan="1">2898</td></tr><tr><td rowspan="1" colspan="1">2.</td><td rowspan="1" colspan="1">BACE1</td><td rowspan="1" colspan="1">Homo sapiens</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">539</td></tr><tr><td rowspan="1" colspan="1">3.</td><td rowspan="1" colspan="1">PSEN1</td><td rowspan="1" colspan="1">Homo sapiens</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">786</td></tr><tr><td rowspan="1" colspan="1">4.</td><td rowspan="1" colspan="1">PSEN2</td><td rowspan="1" colspan="1">Homo sapiens</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">314</td></tr></tbody></table></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><title>BLAT output showing the alignment of APP, BACE1, PSEN1 and PSEN2 contigs sorted by score</title></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1">Query</td><td rowspan="1" colspan="1">Score</td><td rowspan="1" colspan="1">Start</td><td rowspan="1" colspan="1">End</td><td rowspan="1" colspan="1">Qsize</td><td rowspan="1" colspan="1">Identity (%)</td><td rowspan="1" colspan="1">Chromosome</td><td rowspan="1" colspan="1">Strand</td></tr></thead><tbody><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">APP</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Contig1</td><td rowspan="1" colspan="1">547</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">582</td><td rowspan="1" colspan="1">583</td><td rowspan="1" colspan="1">99.9</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Contig1</td><td rowspan="1" colspan="1">515</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">550</td><td rowspan="1" colspan="1">583</td><td rowspan="1" colspan="1">99.9</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1">Contig2</td><td rowspan="1" colspan="1">734</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">752</td><td rowspan="1" colspan="1">780</td><td rowspan="1" colspan="1">99.5</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Contig2</td><td rowspan="1" colspan="1">734</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">757</td><td rowspan="1" colspan="1">780</td><td rowspan="1" colspan="1">99.2</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1">Contig3</td><td rowspan="1" colspan="1">3838</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">3876</td><td rowspan="1" colspan="1">4579</td><td rowspan="1" colspan="1">99.8</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Contig3</td><td rowspan="1" colspan="1">3838</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">3876</td><td rowspan="1" colspan="1">4579</td><td rowspan="1" colspan="1">99.8</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1">Contig4</td><td rowspan="1" colspan="1">1331</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">1340</td><td rowspan="1" colspan="1">1340</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1">Contig4</td><td rowspan="1" colspan="1">1330</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1340</td><td rowspan="1" colspan="1">1340</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">BACE1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Contig5</td><td rowspan="1" colspan="1">1605</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">1616</td><td rowspan="1" colspan="1">1616</td><td rowspan="1" colspan="1">99.9</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1">Contig5</td><td rowspan="1" colspan="1">1604</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">1616</td><td rowspan="1" colspan="1">1616</td><td rowspan="1" colspan="1">99.8</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Contig6</td><td rowspan="1" colspan="1">4916</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">5092</td><td rowspan="1" colspan="1">5184</td><td rowspan="1" colspan="1">99.4</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Contig6</td><td rowspan="1" colspan="1">4916</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">5100</td><td rowspan="1" colspan="1">5184</td><td rowspan="1" colspan="1">99.3</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1">Contig7</td><td rowspan="1" colspan="1">563</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">572</td><td rowspan="1" colspan="1">572</td><td rowspan="1" colspan="1">99.7</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Contig7</td><td rowspan="1" colspan="1">563</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">572</td><td rowspan="1" colspan="1">572</td><td rowspan="1" colspan="1">99.7</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1">PSEN1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Contig8</td><td rowspan="1" colspan="1">546</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">589</td><td rowspan="1" colspan="1">589</td><td rowspan="1" colspan="1">99.7</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Contig8</td><td rowspan="1" colspan="1">545</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">589</td><td rowspan="1" colspan="1">589</td><td rowspan="1" colspan="1">99.7</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1">Contig9</td><td rowspan="1" colspan="1">4161</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">4265</td><td rowspan="1" colspan="1">4265</td><td rowspan="1" colspan="1">99.6</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1">Contig9</td><td rowspan="1" colspan="1">4159</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">4265</td><td rowspan="1" colspan="1">4265</td><td rowspan="1" colspan="1">99.6</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Contig10</td><td rowspan="1" colspan="1">465</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">477</td><td rowspan="1" colspan="1">604</td><td rowspan="1" colspan="1">98.8</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Contig10</td><td rowspan="1" colspan="1">464</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">478</td><td rowspan="1" colspan="1">604</td><td rowspan="1" colspan="1">98.6</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1">Contig11</td><td rowspan="1" colspan="1">1491</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1501</td><td rowspan="1" colspan="1">1680</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Contig11</td><td rowspan="1" colspan="1">1491</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1505</td><td rowspan="1" colspan="1">1680</td><td rowspan="1" colspan="1">99.9</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1">Contig12</td><td rowspan="1" colspan="1">501</td><td rowspan="1" colspan="1">44</td><td rowspan="1" colspan="1">638</td><td rowspan="1" colspan="1">638</td><td rowspan="1" colspan="1">99.5</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1">Contig12</td><td rowspan="1" colspan="1">499</td><td rowspan="1" colspan="1">38</td><td rowspan="1" colspan="1">638</td><td rowspan="1" colspan="1">638</td><td rowspan="1" colspan="1">98.7</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">PSEN2</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Contig13</td><td rowspan="1" colspan="1">577</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">580</td><td rowspan="1" colspan="1">580</td><td rowspan="1" colspan="1">99.9</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Contig13</td><td rowspan="1" colspan="1">577</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">580</td><td rowspan="1" colspan="1">580</td><td rowspan="1" colspan="1">99.9</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1">Contig14</td><td rowspan="1" colspan="1">1499</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1602</td><td rowspan="1" colspan="1">1918</td><td rowspan="1" colspan="1">98.4</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Contig14</td><td rowspan="1" colspan="1">1467</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1603</td><td rowspan="1" colspan="1">1918</td><td rowspan="1" colspan="1">97.9</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">+</td></tr></tbody></table></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><title>The InterProScan annotations for Hypothetical protein</title></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1">Protein</td><td rowspan="1" colspan="1">GENE3D</td><td rowspan="1" colspan="1">PANTHER</td><td rowspan="1" colspan="1">PFAM</td><td rowspan="1" colspan="1">PRINTS</td><td rowspan="1" colspan="1">PROFILE</td><td rowspan="1" colspan="1">SMART</td><td rowspan="1" colspan="1">SUPER FAMILY</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Contig3</td><td rowspan="1" colspan="1">G3DSA:</td><td rowspan="1" colspan="1">PTHR23103</td><td rowspan="1" colspan="1">PF12925; </td><td rowspan="1" colspan="1">PR00204</td><td rowspan="1" colspan="1">PS00319; 00280; </td><td rowspan="1" colspan="1">SM000006; 000131</td><td rowspan="1" colspan="1">SF10984; </td></tr><tr><td rowspan="1" colspan="1">/APP</td><td rowspan="1" colspan="1">3.90.570.10; </td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">PF02177;</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">320</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">56491; </td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1.10.287.510; </td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"> PF12924 </td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">89811; </td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">4.10.410.10</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">and </td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">57362</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">PF00014</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><table-wrap id="T4" position="float"><label>Table 4</label><caption><title>Molecular docking analysis of modeled APP protein with synthetic and medicinal compounds</title></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1">S.No</td><td rowspan="1" colspan="1">Compound Name</td><td rowspan="1" colspan="1">Glide Score (Kcal/mol)</td><td rowspan="1" colspan="1">No.of Hydrogen Bonds</td><td rowspan="1" colspan="1">Interacting Residues</td><td rowspan="1" colspan="1">Ligand Atom</td><td rowspan="1" colspan="1">Distance Length (&#x000c5;)</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">1.</td><td rowspan="1" colspan="1">Curcumin</td><td rowspan="1" colspan="1">-8.7</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">ARG566:HE</td><td rowspan="1" colspan="1">O</td><td rowspan="1" colspan="1">2.3</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">ARG566:HE</td><td rowspan="1" colspan="1">O</td><td rowspan="1" colspan="1">2.5</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">ARG566: 1HH2</td><td rowspan="1" colspan="1">O</td><td rowspan="1" colspan="1">1.9</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">VAL673:O</td><td rowspan="1" colspan="1">H</td><td rowspan="1" colspan="1">2.7</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">VAL673:O</td><td rowspan="1" colspan="1">H</td><td rowspan="1" colspan="1">2.1</td></tr><tr><td rowspan="1" colspan="1">2.</td><td rowspan="1" colspan="1">Ginsenoside </td><td rowspan="1" colspan="1">-6.1</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">VAL673:O</td><td rowspan="1" colspan="1">H</td><td rowspan="1" colspan="1">1.9</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Rb1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">LYS680:H</td><td rowspan="1" colspan="1">O</td><td rowspan="1" colspan="1">1.9</td></tr><tr><td rowspan="1" colspan="1">3.</td><td rowspan="1" colspan="1">Aristolene </td><td rowspan="1" colspan="1">-5.2</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">PHE745:O</td><td rowspan="1" colspan="1">H</td><td rowspan="1" colspan="1">2.41</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">epoxide</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">GLU747:O</td><td rowspan="1" colspan="1">H</td><td rowspan="1" colspan="1">2.21</td></tr><tr><td rowspan="1" colspan="1">4.</td><td rowspan="1" colspan="1">Phytol acetate</td><td rowspan="1" colspan="1">-3.8</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">SER711:O</td><td rowspan="1" colspan="1">H</td><td rowspan="1" colspan="1">1.98</td></tr><tr><td rowspan="1" colspan="1">5.</td><td rowspan="1" colspan="1">Dimethoxane</td><td rowspan="1" colspan="1">-3.6</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">GLY677:O</td><td rowspan="1" colspan="1">H</td><td rowspan="1" colspan="1">2.01</td></tr><tr><td rowspan="1" colspan="1">6.</td><td rowspan="1" colspan="1">Valeranone</td><td rowspan="1" colspan="1">-3.6</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">LYS680:O</td><td rowspan="1" colspan="1">H</td><td rowspan="1" colspan="1">1.69</td></tr><tr><td rowspan="1" colspan="1">7.</td><td rowspan="1" colspan="1">Erucic acid</td><td rowspan="1" colspan="1">-3.5</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">LYS680:H</td><td rowspan="1" colspan="1">O</td><td rowspan="1" colspan="1">2.37</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">ASP720:O</td><td rowspan="1" colspan="1">H</td><td rowspan="1" colspan="1">1.8</td></tr><tr><td rowspan="1" colspan="1">8.</td><td rowspan="1" colspan="1">Rivastigmine</td><td rowspan="1" colspan="1">-2.9</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">LYS600:O</td><td rowspan="1" colspan="1">H</td><td rowspan="1" colspan="1">1.99</td></tr><tr><td rowspan="1" colspan="1">9.</td><td rowspan="1" colspan="1">Tacrine</td><td rowspan="1" colspan="1">-1.4</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">ASP720:O</td><td rowspan="1" colspan="1">H</td><td rowspan="1" colspan="1">1.66</td></tr><tr><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">Galantamine</td><td rowspan="1" colspan="1">-1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">ASP720:O</td><td rowspan="1" colspan="1">H</td><td rowspan="1" colspan="1">1.51</td></tr><tr><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">Donepezil</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td></tr></tbody></table></table-wrap><fig id="F1" position="float"><label>Figure 1</label><caption><p>Graphical representation of contig protein sequences obtained from ESTscan2 translation sequences. Red color box represents X error translate level in APP 
(Contig 1, 2, 4), BACE1 (5, 6, 7), PSEN1 (8,9,11) and PSEN2 (14) except APP contig 3 sequence.</p></caption><graphic xlink:href="97320630015760F1"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p>Graphical representation of modelled and validated hypothetical protein of APP. A) Domain regions of red color show APP N (Amyloid A4 N-terminal heparin binding); 
Blue color is APP Cu bd (Copper-binding of amyloid precursor, CuB); Yellow color is Kunitz BPTI (Kunitz/Bovine pancreatic trypsin inhibitor); Magenta color is APP E2 (E2 domain 
of amyloid precursor protein); Cyan color is &#x003b2;-amyloid and Orange color is APP C (APP-amyloid). B) Verify 3D plot showed score ranges in between -1.0 to 0.7. </p></caption><graphic xlink:href="97320630015760F2"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p>Interaction of modeled protein APP docked with curcumin. Light orange color represents protein; green color is curcumin compound and 
blue color is interacted residues.</p></caption><graphic xlink:href="97320630015760F3"/></fig></floats-group></article>